In vitro resistance studies with bacteria that exhibit low mutation frequencies: Prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 1014-1019

  Firsov, Alexander A ^a   Golikova, Maria V ^a   Strukova, Elena N ^a   Portnoy, Yury A ^a   Romanov, Andrey V ^b   Edelstein, Mikhail V ^b   Zinner, Stephen H ^c  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b SMOLENSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^c MOUNT AUBURN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL STRAIN; COLONY FORMING UNIT; IN VITRO STUDY; INOCULATION; LIMIT OF DETECTION; LINEZOLID-RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; DRUG EFFECTS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; LINEZOLID; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MUTATION RATE; OXAZOLIDINONES; STAPHYLOCOCCUS AUREUS;

EID: 84921925286     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04214-14     Document Type: Article

References (43)

1. Meka VG, Gold HS. 2004. Antimicrobial resistance to linezolid. Clin Infect Dis 39:1010-1015. http://dx.doi.org/10.1086/423841.
2. Moellering RC. 2003. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 138:135-142. http://dx.doi.org/10.7326/0003-4819-138 -2-200301210-00015.
3. Miller K, Dunsmore CJ, Fishwick CW, Chopra I. 2008. Linezolid and tiamulin cross-resistance in Staphylococcus aureus mediated by point mutations in the peptidyl transferase center. Antimicrob Agents Chemother 52:1737-1742. http://dx.doi.org/10.1128/AAC.01015-07.
4. Clark C, Kosowska-Shick K, McGhee P, Dewasse B, Beachel L, Appelbaum PC. 2009. Resistance selection studies comparing the activity of razupenem (PTZ601) to vancomycin and linezolid against eight methicil-lin-resistant and two methicillin-susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 53:3118-3121. http://dx.doi.org/10.1128 /AAC.00183-09.
5. Locke JB, Hilgers M, Shaw KJ. 2009. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother 53:5265-5274. http://dx.doi.org/10.1128/AAC.00871-09.
6. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358:207-208. http://dx .doi.org/10.1016/S0140-6736(01)05410-1.
7. Wilson P, Andrews JA, Charlesworth R, Walesby R, Singer M, Farrell DJ, Robbins M. 2003. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 51:186-188. http://dx.doi.org /10.1093/jac/dkg104.
8. Meka VG, Gold HS, Cooke A, Venkataraman L, Eliopoulos GM, Moellering RC, Jenkins SG. 2004. Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus. J Antimicrob Chemother 54:818-820. http://dx.doi.org/10.1093/jac/dkh423.
9. Hentschke M, Saager B, Horstkotte MA, Scherpe S, Wolters M, Kabisch H, Grosse R, Heisig P, Aepfelbacher M, Rohde H. 2008. Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain. Infection 36:85-87. http://dx.doi.org/10.1007/s15010-007-7220-7.
10. Gales AC, Sader HS, Andrade SS, Lutz L, Machado A, Barth AL. 2006. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents 27:300-302. http://dx.doi.org/10.1016/j.ijantimicag.2005.11.008.
11. Meka VG, Pillai SK, Sakoulas G, Wennersten C, Venkataraman L, DeGirolami PC, Eliopoulos GM, Moellering RC, Gold HS. 2004. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 190:311-317. http://dx.doi.org/10.1086/421471.
12. Yoshida K, Shoji H, Hanaki H, Yanagisawa C, Ikeda-Dantsuji Y, Fukuchi K, Adachi M, Niki Y. 2009. Linezolid-resistant methicillinresistant Staphylococcus aureus isolated after long-term, repeated use of linezolid. J Infect Chemother 15:417-419. http://dx.doi.org/10.1007 /s10156-009-0727-3.
13. Hill RL, Kearns AM, Nash J, North SE, Pike R, Newson T, Woodford N, Calver R, Livermore DM. 2010. Linezolid-resistant ST36 methicillinresistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. J Antimicrob Chemother 65:442-445. http://dx.doi.org/10.1093/jac/dkp494.
14. Ikeda-Dantsuji Y, Hanaki H, Nakae T, Takesue Y, Tomono K, Honda J, Yanagihara K, Mikamo H, Fukuchi K, Kaku M, Kohno S, Niki Y. 2011. Emergence of linezolid-resistant mutants in a susceptible-cell population of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 55:2466-2468. http://dx.doi.org/10.1128/AAC.01548-10.
15. Locke JB, Hilgers M, Shaw KJ. 2009. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob Agents Chemother 53:5275-5278. http://dx.doi.org /10.1128/AAC.01032-09.
16. Smirnova MV, Stukova EN, Portnoy YA, Dovzhenko SA, Kobrin MB, Zinner SH, Firsov AA. 2011. The antistaphylococcal pharmacodynamics of linezolid alone and in combination with doxycycline in an in vitro dynamic model. J Chemother 23:140-144. http://dx.doi.org/10.1179/joc .2011.23.3.140.
17. Boak LM, Li J, Rayner CR, Nation RL. 2007. Pharmacokinetic/ pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents Chemother 51: 1287-1292. http://dx.doi.org/10.1128/AAC.01194-06.
18. Cha R, Brown WJ, Rybak MJ. 2003. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 47:3960-3963. http://dx.doi.org/10.1128/AAC.47.12.3960-3963.2003.
19. LaPlante KL, Rybak MJ. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 48:4665-4672. http://dx .doi.org/10.1128/AAC.48.12.4665-4672.2004.
20. Ba BB, Arpin C, Bikie Bi Nso B, Dubois V, Saux MC, Quentin C. 2010. Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype. Antimicrob Agents Chemother 54:1443-1452. http://dx.doi.org/10.1128/AAC.01022-09.
21. Dong Y, Zhao X, Domagala J, Drlica K. 1999. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 43:1756-1758.
22. Firsov AA, Smirnova MV, Strukova EN, Vostrov SN, Portnoy YA, Zinner SH. 2008. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion. Int J Antimicrob Agents 32:488-493. http://dx.doi.org/10.1016/j.ijantimicag.2008.06.031.
23. Firsov AA, Shevchenko AA, Vostrov SN, Zinner SH. 1998. Inter- and intra-quinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother 42:659-665.
24. Stalker DJ, Jungbluth GL. 2003. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 42:1129-1140. http://dx.doi.org/10.2165/00003088-200342130-00004.
25. MacGowan AP. 2003. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother 51 (Suppl S2):ii17-ii25.
26. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. 2003. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 47:548-553. http://dx.doi.org/10.1128/AAC.47.2.548-553.2003.
27. Pillai SK, Sakoulas G, Wennersten C, Eliopoulos GM, Moellering RC, Ferraro MJ, Gold HS. 2002. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J Infect Dis 186: 1603-1607. http://dx.doi.org/10.1086/345368.
28. Prunier AL, Malbruny B, Tandé D, Picard B, Leclercq R. 2002. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. Antimicrob Agents Chemother 46:3054-3056. http://dx.doi.org/10.1128/AAC.46.9.3054-3056.2002.
29. Firsov AA, Lubenko IY, Smirnova MV, Strukova EN, Zinner SH. 2008. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob Agents Chemother 52:1924-1928. http://dx.doi.org/10.1128/AAC.01371-07.
30. Firsov AA, Portnoy YA, Strukova EN, Shlykova DS, Zinner SH. 2014. Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations. Int J Antimicrob Agents 44:301-305. http://dx.doi.org/10.1016/j.ijantimicag.2014.06.013.
31. Cui J, Liu Y, Wang R, Tong W, Drlica K, Zhao X. 2006. The mutant selection window in rabbits infected with Staphylococcus aureus. J Infect Dis 194:1601-1608. http://dx.doi.org/10.1086/508752.
32. Li X, Wang L, Zhang XJ, Yang Y, Gong WT, Xu B, Zhu YQ, Liu W. 2014. Evaluation of meropenem regimens suppressing emergence of resistance in Acinetobacter baumannii with human simulated exposure in an in vitro intravenous-infusion hollow-fiber infection model. Antimicrob Agents Chemother 58:6773-6778. http://dx.doi.org/10.1128/AAC.03505-14.
33. Firsov AA, Strukova EN, Shlykova DS, Portnoy YA, Kozyreva VK, Edelstein MV, Dovzhenko SA, Kobrin MB, Zinner SH. 2013. Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations. Antimicrob Agents Chemother 57:4956-4962. http://dx.doi.org/10 .1128/AAC.00578-13.
34. Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH. 2003. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 47:1604-1613. http://dx.doi.org/10 .1128/AAC.47.5.1604-1613.2003.
35. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL. 2007. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother 51: 744-747. http://dx.doi.org/10.1128/AAC.00334-06.
36. Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH. 2006. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 58:1185-1192. http://dx .doi.org/10.1093/jac/dkl387.
37. Smirnova MV, Vostrov SN, Strukova EV, Dovzhenko SA, Kobrin MB, Portnoy YA, Zinner SH, Firsov AA. 2009. The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models. J Antimicrob Chemother 64:815-820. http://dx.doi.org/10 .1093/jac/dkp287.
38. Tsakris A, Pillai SK, Gold HS, Thauvin-Eliopoulos C, Venkataraman L, Wennersten C, Moellering RC, Eliopoulos GM. 2007. Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus. J Antimicrob Chemother 60:649-651. http://dx.doi.org/10.1093/jac/dkm246.
39. Besier S, Ludwig A, Zander J, Brade V, Wichelhaus TA. 2008. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrob Agents Chemother 52: 1570-1572. http://dx.doi.org/10.1128/AAC.01098-07.
40. Miller K, O'Neill AJ, Wilcox MH, Ingham E, Chopra I. 2008. Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents. Antimicrob Agents Chemother 52:1940-1944. http://dx.doi.org/10.1128/AAC.01302-07.
41. Firsov A, Smirnova M, Strukova E, Portnoy Y, Zinner S. 2010. Staphylococcal resistance studies using susceptible organisms supplemented with their resistant mutants: combined treatment with linezolid and gentamicin simulated in an in vitro dynamic model. Abstr 50th Intersci Conf Antimicrob Agents Chemother, abstr A1-006.
42. Firsov A, Smirnova M, Strukova E, Portnoy Y, Zinner S. 2011. Staphylococcal resistance studies using susceptible organisms supplemented with their resistant mutants: linezolid and rifampin combinations simulated in an in vitro dynamic model. Abstr 21st Eur Congr Clin Microb Infect Dis, abstr O80.
43. Zinner SH, Gilbert D, Lubenko IY, Greer K, Firsov AA. 2008. Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline. J Antimicrob Chemother 61:629-635. http://dx.doi.org/10.1093/jac/dkm542.